Sarah -
It's often interesting to see what mainstream news outlets pick up regarding mental health and addiction research. CNN in the states has a compelling piece today on a 2021 study comparing the longer-term results of SSRI vs. psilocybin for depression treatment.
Psilocybin: Searching for the antidepressant of the future | CNN
Presented by SickKids CCMH Learning Institute
Presented by SickKids CCMH Learning Institute
Vincent -
Clinicians have proven few pharmacological and psychotherapeutic treatments effective for body dysmorphic disorder (BDD) and eating disorders (ED). However, researchers are exploring new treatment options for those with EDs and BDD including psychedelic-assisted therapies. This systematic review collected and evaluated evidence related to the therapeutic impact psychedelics have on patients diagnosed with EDs and BDD.
Presented by SickKids CCMH Learning Institute
You’re invited for EHN Canada’s next educational webinar: Psychedelics in the Treatment of Substance Use Disorders with Dr. Ian King, BMSc, MD, FRCPC, DRCPSC (Addiction Medicine), Psychiatrist, Edgewood Treatment Centre.
Are you curious about psychedelics and their potential for improving mental health and substance use health? In this HRI Talk, we explore emerging evidence about the use of psychedelic therapies in the treatment of mental illness and addictions.
Rupi -
Rupi -
This webinar is presented by CAMH’s Institute for Mental Health Policy Research.
Join a special talk by Professor Roland R. Griffiths.
Registration is now open for #R2R2022!
This international conference is being planned by the Centre for Addiction and Mental Health (CAMH) in collaboration with the Canadian Centre on Substance Use and Addiction (CCSA) and the Mental Health Commission of Canada (MHCC).
The goal of the conference is to bring policymakers, researchers, and clinicians together, in the interest of moving psychedelics research forward into both policy and practice.
Shared from the Canadian Drug Policy Coalition (www.drugpolicy.ca):
What you need to know
On October 28th, EENet hosted a webinar featuring a conversation among key experts in the field of psychedelics research. Panelists discussed their viewpoints on ensuring psychedelic therapies are safe for everyone who could benefit from them, including issues related to regulation, standards of training, and cultural competence.
Ensuring safety for all in psychedelic medicine will be hosted by EENet at 1:00 PM Eastern Time on Thursday, October 28th.
Our panel of experts will be discussing their viewpoints on ensuring psychedelic therapies are safe for everyone who could benefit from them, including issues related to regulation, standards of training, and cultural competence.
Rossana -
You are invited to join tomorrow's (Wednesday's) Live FAQ session from 9 to 11 AM on the Ontario Common Assessment of Need (OCAN), the standardized assessment tool used in the community mental health sector.
During this time, OCAN experts will provide written responses to stakeholder questions using CAMH’s EENET Connect online space.
HOW TO PARTICIPATE:
Join us for a webinar hosted by EENet that will feature a conversation among key experts in the psychedelics field. Panelists will discuss their viewpoints on ensuring psychedelic therapies are safe for everyone who could benefit from them, including issues related to regulation, standards of training, and cultural competence. Discussion will be followed by a Q&A period.
Speakers:
The Canadian Network for Bioma
Psychedelics such as psilocybin, lysergic acid diethylamide (LSD) and Ketamine have long been excluded from mental therapeutic treatments due to stigmatization and lack of understanding. In recent years however, researchers and scientists have begun to unearth new discoveries and research in relation to the effectiveness of these substances in the treatment of depression, anxiety, and other mental health challenges.
May 11, 2021 10:00 AM
